SBIR/STTR Research Award

Novel Multiplex Assay for Biomarkers of Obstructive Nephropathy

Award identifier c8e734372036c38fdc30fc1da4512d9a1b9f7c094202ae10959e83f9df8639beAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$106,050

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Panorama Research Incorporated
Proposal award date
Not reported
Contract end date
Not reported
UEI
LYVHC3ARFRJ7
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Congenital obstructive nephropathy is the most frequent cause of renal failure in infants and children, and if left untreated can cause severe renal failure and death. Challenges in the evaluation and management include the lack of clear indications if and when surgical intervention is indicated, the use of controversial invasive diagnostic tests that may employ radiation, and the requirement for long-term follow-up to monitor disease progression that often occurs despite surgical correction. The goal of this proposal is to develop a sensitive multiplex assay of urinary biomarkers of renal inflammation and cell injury to aid the diagnosis, prognosis, therapeutic decision-making, and monitoring of patient therapy. We have developed a proprietary technology using the real-time-polymerase chain reaction (PCR) technology to measure protein concentrations in a multiplexed fashion with very high sensitivity and reproducibility called Multiplexed Real-time-Immuno-PCR (MRI-PCR). In Phase I studies, a panel of reagents to detect human biomarkers of obstructive nephropathy will be prepared and evaluated in the MRI-PCR assay. A comprehensive analytical validation of the MRI-PCR assay will be performed by measuring sensitivity, specificity, accuracy, and dilutional linearity of each analyte. The performance will be verified by spiking known concentrations of each of the analytes into normal urine. In Phase II, the assay will be validated by testing urine samples from patients with congenital urinary tract obstruction as well as urine from healthy children. The successful completion of this project will result in an assay of multiple urinary biomarkers to aid clinicians and researchers in the evaluation and management of congenital obstructive nephropathy. Although the initial focus is on neonatal and childhood urinary tract obstructions, ultimately this assay may be useful for adults with obstructed nephropathy and perhaps other types of renal diseases. Congenital obstructive nephropathy is a common disease in neonate that is difficult to clinically assess without the use of invasive imaging modalities. This proposal will develop a non-invasive new technology that will simultaneously measure a panel of urinary biomarkers associated with obstructed urinary tract diseases that is expected to be useful for diagnosis, prognosis, guiding therapeutic intervention, and long-term monitoring of responses to therapy or disease progression.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

149 SBIR/STTR records share this UEI (1990–2025). Reported award amounts total $35,373,004. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.